Estimated reading time: 2 minutes
A recent report shed light on the substantial impact of Alzheimer's Disease and related dementia (ADRD) on healthcare costs. This came from Sage Growth Partners (SGP), a prominent healthcare research, strategy, and marketing firm. The report is based on insights from over 50 senior leaders of health plans and value-based care organizations. It showcases a pattern of inaction from healthcare organizations. This prevents them from addressing the financial, physical and emotional tolls of ADRD, despite awareness of the problem.
"Fortunately, healthcare leaders are beginning to recognize the urgency of addressing ADRD and acknowledge that they must develop and enact dementia-specific strategies," said Dan D'Orazio, CEO, Sage Growth Partners. "However, our recent findings show that organizations are surprisingly slow to implement cost-effective and outcome-oriented approaches."
Some key findings were:
- 77% of respondents recognize Alzheimer's and dementia as an urgent priority, but only 4% claim to have a strategy in place.
- 70% of health plan and value-based care leaders would be motivated to act if ADRD spending exceeded that of other high-cost conditions.
- 69% of respondents are looking for innovative, non-drug interventions.
The report highlights the slow implementation of cost-effective, outcome-oriented approaches. This is coupled with the prevalence of rising costs as a driving force behind adopting non-pharmaceutical interventions. There is a need for healthcare organizations to address the financial, physical, and emotional tolls of ADRD with a more proactive and strategic approach.
Interested in more health news? Create a free PatientsLikeMe account today!